DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Miscellaneous
BB Biotech AG admitted to the SMIM and SPI Index
09-Jul-2018 / 18:10 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Media release as of July 9, 2018
BB Biotech AG admitted to the SMIM and SPI Index
After the SIX Swiss Exchange's latest regular review of index components, BB Biotech was admitted to the SMIM Index and the SPI Index (sub-index SPI Mid). The composition of the two indices will be adjusted after the close of trading on September 21, 2018, effective as of September 24, 2018.
BB Biotech was previously admitted to the Stoxx Europe 600 in 2014 due to its growing market capitalization and trading liquidity. "BB Biotech's admission to the SMIM Index reflects our successful performance in the highly attractive market of biotechnology," declares Dr. Daniel Koller, Head of BB Biotech's Investment Team. "With almost 25 years of experience and an investment portfolio of around CHF 3.5 bn, we are one of the largest investors in this field."
The SMI family, the most widely followed group of indices compiled by SIX Swiss Exchange, comprises the 50 largest and most liquid stocks in the Swiss stock market. The blue-chip SMI Index is the most prestigious index of stocks listed in Switzerland and comprises the 20 largest stocks from the SPI. The SMIM, in which BB Biotech will be a member effective September 24, 2018, comprises the next 30 largest and most liquid stocks from the mid cap segment of the SPI. All SMI and SMIM stocks are included in the SMI Expanded Index, which covers more than 90% of the Swiss stock market's entire capitalization.
TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, tel. +41 79 423 22 28
Thomas Egger, teg@te-communications.ch
www.bbbiotech.com
Company profile
BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.
09-Jul-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English
Company:
BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone:
+41 52 624 08 45
E-mail:
info@bbbiotech.com
Internet:
www.bbbiotech.ch
ISIN:
CH0038389992
WKN:
A0NFN3
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX
BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Companyâs portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.